Impact of Research and Innovation Scale (IRIS) Latest News
- The Indian Council of Medical Research (ICMR) has proposed the Impact of Research and Innovation Scale (IRIS) to measure the impact of biomedical, public health, and allied research projects.
- Given ICMR’s role as India’s premier grants-giving and agenda-setting body in health research, IRIS could significantly shape the research ecosystem.
Key Features of IRIS
- ICMR proposes to measure research impact in units called publication-equivalents (PEs).
- A research paper published in a peer-reviewed journal that reports results or methods of primary research, or a systematic review and meta-analysis is assigned 1 PE.
- While a research paper that is cited in policies or guidelines is assigned 10 PEs.
- A patent’s impact is 5 PEs and that of a commercial device being used at scale is 20 PEs.
Advantages of IRIS
- Standardisation - Uniform metric: IRIS provides a common yardstick across disciplines (biochemistry, physiology, biomedical engineering, public health, etc).
- Recognition beyond citations: Breaks the conventional citation-driven incentive system and encourages diverse forms of impactful research.
- Policy and funding linkage: By tying PEs to funding allocation, IRIS can influence research prioritisation and resource distribution effectively.
Concerns and Limitations
- Theoretical weakness:
- PE assignment lacks strong theoretical rationale.
- It excludes influential works. For example, commentary, perspective, and narratives review papers will have 0 PE.
- In this case, the 1977 paper that introduced the biopsychosocial model of medicine, which transformed medical and public health research, will have no impact.
- Articulating new ideas and critical discourse around emerging evidence are at the foundation of research, yet the PE-based system could discourage Indian researchers from pursuing articles of this nature.
- Skewed incentives:
- It prioritises commercial devices (20 PEs) over policy-level interventions (10 PEs).
- Risks undervaluing basic science, public health programmes, and academic medicine.
- For example, the RATIONS clinical trial (studied nutrition in tuberculosis patients) and India’s Home-Based Neonatal Care (revolutionised community health programming) will be deemed to be less impactful.
- Risk to research as a public good:
- Over-commercialisation may erode the ethos of science as a public good.
- Potential misuse in India’s already weak research ethics culture.
- Need for transparency:
- Development of IRIS requires rigorous methods, accountability, and peer validation.
- Suggested approach:
- The assignment of PEs to different indicators could be done through a national-level Delphi study where researchers form a consensus on the assignment.
- Data must be shared with independent groups to analyse and validate the scale.
Conclusion
- Measuring research impact is inherently complex, with no universally correct model.
- ICMR must ensure transparency, inclusivity, and ethical safeguards while developing IRIS.
- Balance is essential to incentivise innovation and translation into practice without undermining fundamental research and critical academic discourse.
- Ultimately, research evaluation must align with India’s public health priorities and uphold research as a public good.
Source: TH
Impact of Research and Innovation Scale (IRIS) FAQs
Q1: What is the Impact of Research and Innovation Scale (IRIS) proposed by ICMR?
Ans: IRIS is a new framework that measures the impact of biomedical and health research using Publication-Equivalents (PEs) as the unit of assessment.
Q2: How does IRIS assign value to different types of research outputs?
Ans: Research papers = 1 PE, policy-cited research = 10 PEs, patents = 5 PEs, commercial devices in use = 20 PEs.
Q3: What are the advantages of introducing a standardised metric like IRIS?
Ans: It provides a uniform benchmark across disciplines, recognises impact beyond citations, and links research output with funding and policy decisions.
Q4: What are the key criticisms of IRIS as a research evaluation tool?
Ans: It may undervalue conceptual and foundational works, skew incentives towards commercialisation, and risk weakening the ethos of research as a public good.
Q5: What measures are suggested to ensure accountability and effectiveness of IRIS?
Ans: Adopting rigorous study design, national-level Delphi consensus, and independent validation mechanisms for assigning PE values.